Story
BlossomHill Therapeutics Slips in Market Debut After $150 Million IPO

Shares of BlossomHill Therapeutics Inc. (NASDAQ: BLSM) declined in their market debut on Friday after the oncology-focused biotechnology company raised $150 million in an upsized U.S. initial public offering.
The stock opened for trading at $15.75, below its IPO price of $16.00 per share, and finished the session down 1.6%, according to market data.
IPO Details
BlossomHill, a clinical-stage biopharmaceutical company based in San Diego, priced its offering of 9,375,000 common shares at $16.00 each on Thursday. The deal was expanded from its original plan to offer 7.8 million shares in a range of $15 to $17, as stated in company filings.
The offering generated gross proceeds of $150 million before deducting underwriting discounts, commissions, and other expenses. The offering is expected to close on August 10, 2026, subject to customary closing conditions.
AdValuation and Underwriters
Based on the number of shares outstanding disclosed in its filings, the IPO gives BlossomHill a market capitalization of approximately $482.6 million. The company has also granted underwriters a 30-day option to purchase up to an additional 1,406,250 shares at the public offering price, less underwriting discounts.
JPMorgan, Leerink Partners, and Guggenheim Securities served as the lead book-running managers for the offering. LifeSci Capital and H.C. Wainwright & Co. acted as co-managers.
Read next
More on Stocks
FTC Orders Walmart, Uber, Delta to Disclose Data on Personalized Pricing
The U.S. Federal Trade Commission is demanding nine major companies, including leading retail, travel, and gig economy firms, to provide information on how they use consumer data for setting individual prices and wages.

Google Launches Gemini 4 Carbon AI Model to Bolster Cybersecurity Capabilities
Alphabet's Google has unveiled Gemini 4 Carbon, its latest AI model specifically designed for advanced cybersecurity tasks like vulnerability detection and secure code generation. The launch escalates competition with rivals OpenAI and Anthropic in the enterprise AI market.

Oracle Shares Surge After Unveiling $225 Billion Revenue Target for 2030
Oracle stock rose sharply after the company presented a long-term financial outlook targeting at least $225 billion in annual revenue by fiscal 2030, driven by its expanding AI infrastructure business.

DOJ Scrutinizes Nvidia's $12.9B Hugging Face Deal Amid Broader Antitrust Probe, Sources Say
The U.S. Department of Justice is reportedly examining Nvidia's planned $12.93 billion acquisition of AI platform Hugging Face as part of a wider, ongoing antitrust investigation into the chipmaker's market conduct.